Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.98 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prochloraz SCHEMBL5838759 | 0.99 | AHR (0.96) | AHRADRB2ADRB1ADRB3MEN1 | |
| Prochloraz SCHEMBL34675 | 0.99 | AHR (1.00) | AHRADRB2ADRB1ADRB3MEN1 | |
| Prochloraz SCHEMBL22242 | 0.99 | AHR (1.00) | AHRADRB2ADRB1ADRB3MEN1 | |
| Prochloraz SCHEMBL10346525 | 0.98 | AHR (0.98) | AHRADRB2ADRB1ADRB3MEN1 | |
| Prochloraz SCHEMBL11381368 | 0.98 | AHR (0.98) | AHRADRB2ADRB1ADRB3MEN1 | |
| Prochloraz SCHEMBL7128363 | 0.98 | AHR (0.98) | AHRADRB2ADRB1ADRB3MEN1 | |
| Prochloraz SCHEMBL9354846 | 0.98 | AHR (0.98) | AHRADRB2ADRB1ADRB3MEN1 | |
| Prochloraz SCHEMBL5581904 | 0.98 | AHR (0.98) | AHRADRB2ADRB1ADRB3MEN1 | |
| Prochloraz SCHEMBL1092013 | 0.98 | AHR (0.98) | AHRADRB2ADRB1ADRB3MEN1 | |
| Prochloraz SCHEMBL9371588 | 0.98 | AHR (0.98) | AHRADRB2ADRB1ADRB3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2328907-B1 | HYDROLASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | DSM IP ASSETS BV (NL) | 2018-12-12 | — | — | EP | claimed |
| EP-1745138-B1 | METHOD FOR FERMENTATIVE PREPARATION OF METHIONINE BY USE OF RECOMBINANT CORYNEFORM BACTERIA | EVONIK DEGUSSA GMBH (DE) | 2010-05-19 | — | — | EP | claimed |
| US-10577315-B2 | Compositions and methods for treatment of prostate carcinoma | PELLFICURE PHARMACEUTICALS, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| EP-3528799-A1 | PHARMACEUTICAL COMPOSITIONS OF 5-HYDROXY-2-METHYLNAPHTHALENE-1, 4-DIONE | Pellficure Pharmaceuticals, Inc. (US) | 2019-08-28 | — | — | EP | disclosed |
| US-20190169122-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | PELLFICURE PHARMACEUTICALS | 2019-06-06 | — | — | US | disclosed |
| US-10093620-B2 | Compositions and methods for treatment of prostate carcinoma | PELLFICURE PHARMACEUTICALS, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-20180221306-A1 | PHARMACEUTICAL COMPOSITIONS OF 5-HYDROXY-2-METHYLNAPHTHALENE-1,4-DIONE | PELLFICURE PHARMACEUTICALS, INC. | 2018-08-09 | — | — | US | disclosed |
| WO-2018089181-A1 | ORGANIC INDOLYL TRIARYLAMINE COMPOUNDS AND ELECTRONIC DEVICES COMPRISING AN ORGANIC LAYER CONTAINING SUCH COMPOUNDS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2018-05-17 | — | — | WO | disclosed |
| WO-2018080933-A1 | PHARMACEUTICAL COMPOSITIONS OF 5-HYDROXY-2-METHYLNAPHTHALENE-1, 4-DIONE | PELLFICURE PHARMACEUTICALS INC. (US) | 2018-05-03 | — | — | WO | disclosed |
| US-20170283374-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | PELLFICURE PHARMACEUTICALS, INC. | 2017-10-05 | — | — | US | disclosed |
| EP-3191087-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | Pellficure Pharmaceuticals, Inc. (US) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016040896-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | PELLFICURE PHARMACEUTICALS, INC. (US) | 2016-03-17 | — | — | WO | disclosed |
| US-20110027264-A1 | GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | SCHERING CORPORATION | 2011-02-03 | — | — | US | disclosed |
| EP-2257542-A1 | GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER ' S DISEASE | Schering Corporation (US) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009108766-A1 | GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER ' S DISEASE | SCHERING CORPORATION (US) | 2009-09-03 | — | — | WO | disclosed |
| US-4400327-A | REACTING A SILYLAMINE WITH A METAL CARBOXYLATE; IN SITU POLYMERIZATION TO FORM POLYURETHANES; FOAMS | UNION CARBIDE CORPORATION (US) | 1983-08-23 | — | — | US | disclosed |
| US-4250298-A | RETENTION AGENTS AND DRAINAGE ACCELERATORS FOR PAPERMAKING | BAYER AKTIENGESELLSCHAFT (DE) | 1981-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10093620-B2 | Compositions and methods for treatment of prostate carcinoma | KLK3, ACP3, NR5A1 | AHR 1260/4885ADRB2 1738/4885ADRB1 1423/4885 |
| US-20190169122-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | KLK3, ACP3, NR5A1 | AHR 1260/4885ADRB2 1738/4885ADRB1 1423/4885 |
| US-20180221306-A1 | PHARMACEUTICAL COMPOSITIONS OF 5-HYDROXY-2-METHYLNAPHTHALENE-1,4-DIONE | DHPS, SRD5A2, SRD5A1 | AHR 842/4885ADRB2 1040/4885ADRB1 1225/4885 |
| US-20170283374-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | KLK3, ACP3, NR5A1 | AHR 1260/4885ADRB2 1738/4885ADRB1 1423/4885 |
| US-20110027264-A1 | GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BACE1, BACE2, PSEN1 | AHR 4107/4885ADRB2 1606/4885ADRB1 897/4885 |
| US-10577315-B2 | Compositions and methods for treatment of prostate carcinoma | KLK3, ACP3, NR5A1 | AHR 1260/4885ADRB2 1738/4885ADRB1 1423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.